Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference2%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe website has added new features, while several detailed data fields and options for downloading study information in various formats have been removed.SummaryDifference3%
- Check36 days agoChange DetectedSeveral links related to rare diseases and clinical trials have been removed, indicating a potential update or restructuring of the website's resources.SummaryDifference0.4%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, with new additions including links to rare disease information, clinical trial documents, and a search feature for Cabozantinib, while the previous version v2.12.1 has been removed.SummaryDifference3%
- Check51 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.